CTLA4 and neoplasm: Cancer immunotherapy, with the recent focus on immune checkpoint blockades (ICB), is a revolutionary approach and has shown great clinical benefit in multiple tumor types with an intent to “cure.” ICB therapies, such as anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1) antibodies, have clinical response rates in the range 10–35% as single agents [1], and the anti-tumor response is not sufficient in many patients and responses are more common in specific tumor types.